Genflow Secures Fully Funded LNP Collaboration With Acuitas to Advance SIRT6 Gene Therapy

Genflow Biosciences Plc ( (GB:GENF) ) just unveiled an announcement.

Genflow Biosciences has entered a strategic technology collaboration with Acuitas Therapeutics, gaining fully funded, non-dilutive access to Acuitas’ clinically validated lipid nanoparticle platform to deliver its SIRT6 mRNA payload. The deal allows Acuitas to formulate Genflow’s SIRT6 mRNA using its LNP technology for preclinical studies, offering third-party validation of Genflow’s science and expanding the potential reach and commercial appeal of its age-related disease pipeline.

The agreement, which carries no cash cost to Genflow and is not expected to impact near-term revenue, establishes a framework for potential deeper development and strategic partnerships subject to preclinical outcomes. Data from the collaboration are intended to guide delivery optimisation, tissue targeting, and future partnering or licensing decisions, supporting a more capital-efficient, de-risked path toward clinical development and potentially strengthening Genflow’s positioning in the mRNA and longevity therapeutics markets.

Spark’s Take on GENF Stock

According to Spark, TipRanks’ AI Analyst, GENF is a Neutral.

The score is primarily constrained by weak financial performance (no revenue, ongoing losses, continued cash burn) and a weakened balance sheet with negative equity. Technicals are moderately supportive given the price trend above key moving averages, but valuation remains pressured due to losses and no dividend support.

To see Spark’s full report on GENF stock, click here.

More about Genflow Biosciences Plc

Genflow Biosciences Plc is a UK-headquartered biotechnology company with R&D facilities in Belgium, developing gene therapies for age-related diseases to promote longer and healthier lives. Its lead candidate, GF-1002, delivers a centenarian variant of the SIRT6 gene and is being evaluated in a proof-of-concept trial in aged dogs and in a planned clinical programme for MASH, a prevalent chronic liver disease lacking effective treatments.

Average Trading Volume: 2,583,179

Technical Sentiment Signal: Buy

Current Market Cap: £11.25M

See more data about GENF stock on TipRanks’ Stock Analysis page.